Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
13.19
+0.41 (3.21%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Atrium Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Atrium Therapeutics stock have an average target of 25, which predicts an increase of 89.54% from the current stock price of 13.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Atrium Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | May '26 | Jun '26 |
|---|---|---|---|
| Strong Buy | 1 | 2 | 3 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $25 | Buy | Initiates | $25 | +89.54% | Jun 18, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $25 | Buy | Initiates | $25 | +89.54% | May 15, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $25 | Buy | Initiates | $25 | +89.54% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
21.60M
from 18.62M
Increased by 16.02%
Revenue Next Year
2.67M
from 21.60M
Decreased by -87.65%
EPS This Year
-3.59
EPS Next Year
-5.85
from -3.59
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 25.6M | 8.0M | |
| Avg | 21.6M | 2.7M | |
| Low | 19.6M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.5% | -63.0% | |
| Avg | 16.0% | -87.7% | |
| Low | 5.3% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -3.59 | -5.85 | |
| Avg | -3.59 | -5.85 | |
| Low | -3.59 | -5.85 |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.